Xilas CEO, Don Lawson, Comments on Today's Opening of the DM (Disease Management) Leadership Forum
Posted on: Monday, 17 October 2005, 12:00 CDT
The following quotes may be attributed to Don Lawson, CEO of Xilas Medical, Inc., regarding today's opening of the DM (Disease Management) Leadership Forum in San Diego.
"Disease Management (DM) has taken shape over the past several years and is demonstrating the promise to deliver better healthcare at a lower cost. In dealing with the escalating costs associated with chronic diseases, we must continue to develop new programs, processes, and the delivery of innovative solutions for people with chronic diseases."
"Vendors and providers of Disease Management products and services must learn to become culturally aware of the ever growing presence of minorities who will be served by our industry. Sensitivity to cultural mores must include taking steps to decrease morbidities for chronic diseases."
"Hispanic Americans are faced with serious health challenges because of the increased prevalence of diabetes in this population. The greater number of risk factors for diabetes in Hispanics, the greater incidence of several diabetes complications such as lower extremity amputations, and the growing number of people of Hispanic ethnicity in the U.S. all contribute to a significant healthcare problem. Hispanic Americans are the second-largest and fastest growing minority group in the U.S., currently representing 11% of the population and expected to grow to 25% by 2050. On average, Hispanic Americans are twice as likely to have diabetes than non-Hispanic whites."
"We are in the midst of a dramatic transformation of our industry which requires new models aimed at improving patient satisfaction, improved clinical outcomes and the reduction of hospital expenditures."
"Disease Management providers should consider innovative ways to develop new products and services that could be delivered through retail partners such as Target, Wal-Mart, CVS, Rite Aid, and Walgreens."
EDITOR NOTE: Xilas will be exhibiting in booth number 407 at the DMAA Leadership Forum in San Diego, October 16-18, 2005.
About Xilas Medical, Inc.
Xilas Medical, Inc. develops patented medical devices, which are founded on evidence-based medicine and clinically proven to reduce foot amputations in diabetic patients. Xilas' friction reduction, nerve damage assessment, and temperature management products dramatically decrease health care costs by preventing acute problems and providing patients and doctors with an early warning system of potential foot-related complications. By focusing on prevention, Xilas is bringing about social change in the management of diabetes. For more information, please visit www.xilas.com.
Reader Contact Information:
Xilas Medical, Inc., 12665 Silicon Drive, San Antonio, TX 78249; Tel: 210-692-1114; www.xilas.com.
Xilas is a registered trademark of Xilas Medical, Inc. All other trademarks are the property of their respective owners.
Source: Business Wire
Related Articles
- Groundbreaking Diabetes Disease Management Program Honored With URAC National Best Practices Award
- Lipitor 80 Mg Reduced the Risk of Heart Attack and Stroke in Patients With Heart Disease, Type 2 Diabetes and Chronic Kidney Disease
- Diabetes Disease Management Reviewed
- Xilas Medical, Inc. Announces Receipt of $1.0 Million Grant From the Texas Emerging Technology Fund
- Xilas Medical, Inc. Announces Patrick J. McStay to Join Management Team As VP Sales and Marketing
- Introducing Aetna Health Connections(SM) -- An Innovative Approach to Medical Management
- American Healthways Extends Agreement With Blue Cross Blue Shield of Massachusetts; Health Plan Expands Diabetes Disease Management Program
- American Republic and World to Transition Up to 60,000 Health Insurance Customers to Great-West Healthcare's Provider Networks and Medical Management Programs
- Xilas Medical, Inc. Announces Availability of GlideSoft(R) Insole for Diabetic Patients
- Standards of Medical Care in Diabetes
 |
 |
User Comments (0)
RSS Feeds